| Presented by: | The University of Kentucky College of Medicine |
| Lecturer | Owen O'Connor, MD, PhD |
| Approximate duration: | Not available |
| Summary points: | This audiovisual presentation discusses the rationale and preclinical evidence underlying the development of the two major classes of epigenetics-based antineoplastics, patient populations that appear to be most likely to benefit from the use of epigentics-based agents, emrging clinical data on the potential use of these agents for solid tumours in general and lung tumours in particular, and evidence regarding the use of these agents for cutaneous T-cell lymphomas. |
| Accreditation: | The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
The University of Kentucky College of Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits.
Expiration date: January 1, 2007. |
| Other: | |
E-Mail this webcast/CME to a colleague
Targeting Epigenetic Mechanisms for the Treatment of Cancer
Go to webcast/CME
E-Mail this webcast/CME to a colleague
Remind me of this
